QURE — uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: NL
- Exchange: NASDAQ
- Employees: 209
- Website: https://www.uniqure.com
Latest SEC filings for QURE
- SCHEDULE 13G/A — 2026-10-16
- 8-K — 2026-09-29
- 8-K — 2026-09-02
- SCHEDULE 13G — 2026-08-14
- SCHEDULE 13G/A — 2026-08-14
- S-8 — 2026-07-29
- 10-Q — 2026-07-29
- 8-K — 2026-07-29
- SCHEDULE 13G — 2026-07-16
- 424B5 — 2026-06-24
Latest QURE news
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT (GlobeNewswire Inc.)
- — UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop (businesswire.com)
- — uniQure (NASDAQ:QURE) Stock Price Down 5.5% Following Analyst Downgrade
- — Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)
- — uniQure (NASDAQ:QURE) Shares Gap Down on Analyst Downgrade
- — 10 Stocks With Massive Short Squeeze Potential
- — UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights (globenewswire.com)
- — uniQure Plunges on Additional Data From Huntington's Disease Study (Zacks Investment Research)
- — uniQure Plunges on Additional Data From Huntington's Disease Study (zacks.com)
- — uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update
Educational tool only — not investment advice.